Please assess the completion status of the following clinical trial:

Trial Title: Intermittent Hypoxia and Caffeine in Infants Born Preterm

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male and female infants born preterm at ≤30 weeks + 6 days post menstrual age~2. Current treatment with routine caffeine~3. PMA 32 weeks + 0 days - 36 weeks + 6 days~4. Anticipated last dose of routine caffeine will be by 36 weeks + 5 days~5. At least 12 hours of breathing room air with no ventilatory support other than on room air nasal air flow therapy regardless of flow rate, or on room air and receiving nasal CPAP, and relapse not anticipated.~6. Able to tolerate enteral medications~7. It is feasible to administer the first dose of study drug no later than 36 weeks + 6 days PMA~Exclusion Criteria:~1. Intraventricular hemorrhage Grade III-IV or cystic periventricular leukomalacia~2. Current or prior treatment for seizures~3. Current or prior treatment for cardiac arrhythmias~4. Known renal or hepatic dysfunction that in the opinion of the investigator would have a clinically relevant impact on caffeine metabolism~5. Major malformation, inborn error of metabolism, chromosomal abnormality~6. Presence of a condition for which survival to discharge unlikely~7. Social, mental health, logistical or other issues that, in the opinion of the investigator, would impact the ability of the family to complete the study

- Gender: ALL
- Minimum Age: 32 Weeks
- Maximum Age: 36 Weeks
- Healthy Volunteers: f

Study Arms:
- Extended Caffeine Treatment (Type: EXPERIMENTAL): Infants in the extended caffeine treatment arm will, beginning the next day after stopping routine caffeine treatment, receive 5 mg/kg/day of caffeine base and increase to 5 mg/kg/twice-a-day (BID) of caffeine base beginning at 36 weeks + 0 days PMA and continuing the BID doses through 42 weeks + 6 days PMA.
- Placebo (Type: PLACEBO_COMPARATOR): Infants in the placebo arm will, beginning the next day after stopping routine caffeine treatment, receive the equivalent (to study drug) volume of placebo daily and increase to the equivalent (to study drug) volume placebo BID through 42 weeks + 6 days PMA.

Based on this trial design, predict the completion outcome and termination type (if applicable).